Group 1 - The company is focusing on expanding proteome coverage by targeting the detection of 18 to 20 amino acids and increasing sequencing read lengths on the Proteus prototype [1] - The list price for the Proteus has been set at $425,000 to align with academic grant cycles and assist potential customers with long-term capital budgeting [1] Group 2 - The strategic focus has shifted towards building a robust publication pipeline, with 5 manuscripts submitted in 2025 to showcase technology utility in clinical proteomics and pathogen detection [2] - The instrument placement program has successfully secured 17 new customers, which helps maintain user engagement and generate consumable revenue without requiring upfront capital [2] Group 3 - Performance in Q4 2025 was affected by capital spending headwinds, including uncertainties in NIH funding and customer hesitation regarding the next-generation platform [3] - Management is transitioning 2026 into a 'market preparation' year, prioritizing the upcoming Proteus launch over maximizing near-term Platinum Pro capital sales [3] - Revenue guidance for 2026 is approximately $1 million, reflecting a shift towards consumable utilization and service revenue rather than new hardware sales [3] - The commercial launch of Proteus is on track for the end of 2026, with prototype systems currently deployed for internal R&D and manufacturing scale-up [3] - Financial guidance indicates total cash usage of $93 million or less, with a balance sheet designed to fund operations into the second quarter of 2028 [3] - A 25% increase in consumable kit volume is expected in 2026 as the installed base matures and new placement-program users begin running experiments [3] - Future margin expansion is anticipated due to the cost-effectiveness of the Proteus passive nano-well architecture compared to current CMOS-based chips [3]

Core Insights - Quantum-Si is focusing on the development and commercial readiness of its Proteus platform, with an expected launch at the end of 2026, which will impact near-term revenue [4][6][19] Financial Performance - For the full year 2025, Quantum-Si reported revenue of $2.4 million, with a gross profit of $1.2 million and a gross margin of 47% [15] - The company ended 2025 with $215.8 million in cash and equivalents, and for 2026, it projects approximately $1 million in revenue, with adjusted operating expenses capped at $98 million and cash usage at $93 million [5][18][19] Strategic Initiatives - The company has expanded its instrument acquisition options, securing 17 new customers across academic labs, pharma, and biotech, which helps in accessing key opinion leaders [2][6] - Quantum-Si is building a publication pipeline to demonstrate broader applications of its technology, with five manuscripts submitted in 2025 and three new releases in early 2026 [1][6] Product Development - The Proteus platform is expected to launch with a list price of $425,000, and the company is currently focusing on direct capital purchases for this product [8][10] - The company has made progress in its prototype systems, with successful internal deployments for R&D and plans for further manufacturing and delivery of additional instruments [11] Market Positioning - Quantum-Si is targeting higher consumable utilization rates and repeat ordering patterns through new applications in clinical proteomics and rapid pathogen detection [7][6] - The company is also exploring partnership opportunities to enhance its offerings, including artificial intelligence tools for deeper insights from protein sequencing data [7]

Financial Data and Key Metrics Changes - Revenue for Q4 2025 was $451,000, with full-year revenue at $2.4 million, reflecting a gross profit of $1.2 million and a gross margin of 47% for the year [20][21] - Q4 gross margin was 27%, impacted by a higher proportion of consumable revenue compared to hardware sales [20] - Total operating expenses for Q4 2025 were $21.2 million, down from $31.3 million in Q4 2024, while full-year operating expenses were $117.3 million, compared to $110.2 million in 2024 [21][22] Business Line Data and Key Metrics Changes - The company reported a focus on consumable revenue, with expectations of a more than 25% increase in the number of consumable kits run by customers in 2026 [31] - The placement program for instruments has secured 17 new customers, enhancing access to key opinion leaders in the market [6][7] Market Data and Key Metrics Changes - The company anticipates modest capital sales in 2026 due to a focus on preparing the market for the Proteus launch, which is expected at the end of 2026 [5][12] - The NIH funding environment is showing signs of improvement, which may positively impact customer capital spending [50] Company Strategy and Development Direction - The company aims to accelerate commercial adoption, deliver on its innovation roadmap, and preserve financial strength as it prepares for the Proteus launch [4][18] - The Proteus system is expected to surpass the first-generation technology across key performance metrics, with a list price set at $425,000 to balance premium value and accessibility [12][80] Management Comments on Operating Environment and Future Outlook - Management views 2026 as a transition year, prioritizing long-term platform adoption over short-term revenue maximization [25][27] - The company is committed to maintaining fiscal discipline while ensuring core strategic initiatives are funded appropriately [19][28] Other Important Information - The company has a strong balance sheet with $215.8 million in cash and investments, allowing it to support operations into the second quarter of 2028 [24][26] - Insider ownership remains significant, with no management team members selling shares outside of plan-mandated selling for tax withholdings [28] Q&A Session Summary Question: What are the trends in consumables within the installed base? - The company is seeing consistent purchasing rates from customers, with expectations of a more than 25% increase in consumable kits run by customers in 2026 [30][31] Question: Should we expect very few placements in 2026, with most revenue from consumables? - Yes, the revenue will primarily come from consumables and services, with limited capital equipment sales anticipated [33][34] Question: Can you discuss the launch curve for Proteus? - The launch will likely follow an S-curve, with existing Platinum users transitioning to Proteus and new customers being engaged [36][39] Question: Does the $98 million in guidance for operating expenses include stock compensation? - The adjusted operating expense number excludes stock-based compensation, focusing on cash-oriented expenses [42] Question: Is the price point for Proteus based on secured pre-orders? - No secured orders are in place; the price is released to assist customers in their capital planning [46][47] Question: Will there be a rental program for Proteus? - Currently, only direct capital sales have been announced, with potential for other acquisition models to be evaluated based on market feedback [83]

Quantum-Si Investor Day Summary Company Overview - **Company**: Quantum-Si (NasdaqGM:QSI) - **Event**: 2025 Investor Day - **Date**: November 19, 2025 Industry Context - **Industry**: Proteomics - **Market Size**: Proteomics is described as a massive market with various segments including academic research, pharma, biotech, defense, and agriculture [2][3][4] - **Complexity**: The proteome consists of approximately 20,000 proteins, but the presence of post-translational modifications and isoforms leads to millions of proteoforms, making it a complex challenge [2][3] Key Points and Arguments Proteus Technology - **Proteus Program**: The majority of R&D investment is focused on the Proteus program, which aims to enhance protein sequencing capabilities [2][10] - **Architecture Change**: The Proteus architecture simplifies the imaging system, allowing for a scalable consumable with up to 80 million wells, compared to 2 million in the previous Platinum system [11][12] - **Automation and Affordability**: The new system aims to automate workflows and reduce costs, making deep protein analysis more accessible [7][12] Performance Improvements - **Sequencing Output**: Proteus is expected to produce 1.8 times more alignments per well compared to Platinum, with a significant increase in the number of wells [19][21] - **Sensitivity**: The signal-to-noise ratio (SNR) of Proteus is about twofold higher than that of Platinum, enhancing the detection of binding events [23] - **Long-Range Structural Information**: Proteus can provide deep sequencing capabilities, crucial for understanding post-translational modifications and variants [22] Future Roadmap - **Launch Timeline**: The first integrated systems are expected to be completed in Q1 2026, with a product launch planned for the end of 2026 [25][26] - **Detection of Amino Acids**: The goal is to detect all 20 amino acids by 2027, with 18 expected to be available at the launch of Proteus [48][62] - **AI and Data Utilization**: The company is leveraging AI for binder design and protein structure prediction to accelerate the development of amino acid recognizers [56][62] Additional Important Insights - **Market Challenges**: The complexity of proteomics makes traditional affinity-based approaches impractical for scaling [3][4] - **Technical Risks**: The company has focused on retiring technical risks through prototypes and has demonstrated the feasibility of the new architecture [12][13] - **Investment in R&D**: The company emphasizes that most of its investment is directed towards product development that will reach the market within the next couple of years [38][64] Conclusion Quantum-Si is positioned to make significant advancements in the proteomics field with its Proteus technology, which promises to enhance sequencing capabilities, reduce costs, and improve accessibility. The roadmap indicates a clear path towards achieving the detection of all 20 amino acids, supported by innovative technology and strategic investments in R&D.

Quantum-Si (QSI) FY Conference Summary Company Overview - **Company**: Quantum-Si (QSI) - **Industry**: Life Science Tools and Diagnostics - **Technology**: Next generation protein sequencer utilizing single molecule detection technology for amino acid detection [1][3] Core Points and Arguments Technology and Market Position - Quantum-Si is the first company to commercialize next generation protein sequencing, aiming for de novo sequencing of proteins [3][4] - The technology is currently used for targeted applications, with plans to expand sequencing output and amino acid coverage [4] Market Dynamics - **U.S. Academic Market**: Experiencing slowdowns in capital purchasing; however, consumable purchases from existing customers are ahead of expectations [5][6] - **Biopharma Market**: Positive traction with applications in protein barcoding; the company has increased opportunities from 30 to 60 in this sector [6][7] Capital Acquisition Models - New models for capital acquisition have been introduced, allowing customers to reagent rent or lease the platform, which may enhance long-term customer engagement [9][10] - A six-month evaluation period is set for customers using the device to assess usage and potential purchase [12][13] Sales Cycles - Academic sales cycles have stretched due to funding issues, while biopharma sales cycles remain longer due to the complexity of implementation [15][16] - Biopharma customers are committing significant time and resources, creating high barriers for competitors once contracts are secured [17] Utilization Patterns - Academic customers show episodic usage patterns, while biopharma customers exhibit more consistent purchasing behavior [22][23] - The platform is expected to generate consumable revenue equivalent to its list price of $125,000 annually at scale [25][26] Product Development - The launch of the Platinum Pro sequencer has been successful, offering onboard analysis capabilities and access to dyes for various applications [28][29] - Upcoming products include V3 and V4 library prep kits aimed at expanding amino acid coverage and lowering sample input requirements [31][34] PTM Detection Kits - PTM detection kits are anticipated to significantly expand the customer base and revenue potential, particularly in developed markets [36][39] - The ability to combine pre-sequencing detection with sequencing runs will enhance the depth of protein profiling [38] Future Product: Proteus - The Proteus device, set to launch in 2026, will feature a new optics-based architecture, allowing for higher density and lower production costs [41][44] - The development timeline is on track, with a prototype expected to demonstrate sequencing capabilities by the end of the year [45] AI Integration - AI is being utilized to develop amino acid recognizers and improve kinetic databases, which is expected to accelerate the path to complete proteome coverage [50][52] - The company has screened over a million binder candidates, providing a rich dataset for AI training [55][56] Additional Insights - There is a perception that the potential of Quantum-Si and its technology may be underestimated, particularly regarding the capabilities of the upcoming Proteus device [58][59] - The complexity of protein sequencing presents high barriers to entry for competitors, suggesting a strong market position for Quantum-Si [59][60]

Financial Data and Key Metrics Changes - Revenue for Q2 2025 was $591,000, significantly below expectations, primarily due to a near halt in capital sales of new instruments [7][24] - Gross profit was $351,000, resulting in a gross margin of 59% for the quarter [24] - For the six months ended June 30, 2025, total revenue was $1,400,000, with a gross profit of $837,000 and a gross margin of 58% [25] Business Line Data and Key Metrics Changes - Capital sales of new instruments were the main driver for the revenue decline, while consumable purchases slightly exceeded expectations [7][8] - The installed base of customers is approximately 65% outside the U.S. and 35% within the U.S., encompassing various customer types including academic, industrial, and government research labs [35] Market Data and Key Metrics Changes - The U.S. academic labs experienced a significant slowdown in capital purchases due to NIH funding uncertainties [7][29] - Despite capital market headwinds, consumable purchasing remained consistent across market segments, with government and pharma/biotech accounts showing stable demand [68] Company Strategy and Development Direction - The company aims to accelerate commercial adoption, deliver on its innovation roadmap, and preserve financial strength [6][21] - New instrument acquisition options have been launched to address capital sales headwinds, allowing customers to purchase consumables without upfront capital investment [10][11] - The company remains confident in the long-term market opportunity in proteomics and is focused on growing its installed customer base [11][21] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the impact of NIH funding uncertainties on capital sales and expressed optimism about the potential for growth through new acquisition models [29][30] - The company anticipates that the new models will help capture consumable revenue and improve overall financial performance in the long term [29][70] Other Important Information - The company reported total operating expenses of $30,500,000 for Q2 2025, an increase from $26,800,000 in Q2 2024, while adjusted operating expenses were $23,800,000, slightly down from $24,400,000 [26] - The company ended the quarter with $214,200,000 in cash, cash equivalents, and investments in marketable securities, providing a strong financial position [27][32] Q&A Session Summary Question: How much of the $591,000 revenue is overseas and in pharma/biotech? - The company does not break out revenue by specific segments but noted that 65% of its installed base is outside the U.S. and 35% is within [35] Question: Is $500,000 to $600,000 the bottom for revenue? - Management expressed optimism that this is the bottom and expects gradual improvement, though not instant [36][38] Question: What does a typical placement look like under the new model? - The company offers several models, including capital purchases, reagent rentals, and short-term placements based on consumable revenue potential [40] Question: Are there any trends in leads with the new acquisition opportunities? - Initial data suggests that customers who were previously interested but constrained by capital are now engaging with the new options [46][49] Question: Will Proteus be offered through new models? - Currently, there are no plans to offer Proteus through alternative models; the focus remains on capital sales [61] Question: How is consumable purchasing trending? - Consumable revenue was slightly ahead of expectations, with consistent purchasing across market segments despite capital sales challenges [68] Question: Are the new kits suitable for specific end markets? - The new kits are designed to meet the needs of pharma/biotech customers and are expected to enhance penetration in that segment [72] Question: Is the company considering partnerships or acquisitions given its cash position? - While the company is open to exploring opportunities, the primary focus remains on executing its core technology and business [80][81] Question: If revenue remains soft, where would cuts be made? - The company does not anticipate cuts in the commercial team but will remain targeted in its approach to R&D and operational expenses [85][90]

Core Insights - QuantumSi Incorporated (QSI) is set to report its second-quarter 2025 results on August 5, 2025, with projected revenues of $1.52 million, indicating a growth of 145.2% compared to the same quarter last year [1][9] - The consensus estimate for loss is 16 cents per share, consistent with the loss reported in the previous year [1][9] - QSI has beaten the Zacks Consensus Estimate in three of the last four quarters, with an average surprise of 18.35% [2] Revenue Growth Factors - QSI's first-quarter performance is expected to benefit from increased global traction, having established 23 international distribution partners, with 60% of instruments installed outside the U.S. [3] - The anticipated growth is driven by the adoption of the Platinum Pro system in the pharmaceutical and biotech sectors, alongside stability in R&D spending [4] - Upcoming product releases, including Version 4 Sequencing Kit and Version 3 of Library Preparation Kit, are expected to expand applications and growth opportunities [5] Market Challenges - Despite growth prospects, QSI faces challenges such as a slowdown in new instrument purchases attributed to uncertainties in NIH funding and weaknesses in the U.S. academic market [6][9] - The current Earnings ESP for QSI is 0.00%, and it holds a Zacks Rank of 3, indicating that the model does not predict an earnings beat this time [7]